MedTrace Logo

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

NCT04810104 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-10-14

No results posted yet for this study

Summary

To test for the first time the potential of a nicotinic agonist on cognitive symptoms in people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as PD-MCI.

Conditions

Interventions

DRUG

AZD0328

Active study drug

DRUG

Placebo

Non-active study drug

Sponsors & Collaborators

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Parkinson's UK

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Masaryk University

    collaborator OTHER

  • Norges Parkinsonforbund, Norway

    collaborator UNKNOWN

  • University of Exeter

    collaborator OTHER

  • Stichting Lygature

    collaborator UNKNOWN

  • Innovative Medicines Initiative

    collaborator OTHER

  • King's College London

    lead OTHER

Principal Investigators

  • Dag Aarsland, PhD · King's College London; Stavager Univeristy Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2024-01-31
Completion
2024-04-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810104 on ClinicalTrials.gov